指南与共识流行病学与生物统计医学教育与科研方法

对接受监测管理的低风险癌症患者临床指南推荐的充分性:系统综述

Adequacy of clinical guideline recommendations for patients with low-risk cancer managed with monitoring: systematic review.
指南 / 共识 · J Clin Epidemiol · 2024-02-13

该系统综述汇总了2012至2023年发布的41部国家及国际指南中针对低风险癌症监测的48条推荐,并用AGREE II工具评价指南质量;结果显示所有指南均说明监测适用人群,但仅部分明确检测项目、监测间隔及干预触发条件,除前列腺癌外证据基础薄弱,推荐不一致。

要点

  • 41部指南共48条推荐,其中前列腺癌15条、肾癌11条、甲状腺癌6条、血液肿瘤10条、其他6条。
  • 48条推荐均说明哪些患者符合监测条件,31条明确检测项目,25条给出监测间隔,23条列出干预触发条件。
  • 证据级别越高,推荐越具体,呈强阳性趋势(P=0.001);监测间隔的证据基于专家意见或其他指南。

核心结论

  • 除前列腺癌外,低风险癌症监测的证据基础薄弱,导致临床指南推荐不一致。
  • 文献缺乏直接证据支持监测推荐,指南制定者依赖专家意见、其他指南或间接/非特异性证据。

研究设计与样本

  • 遵循PRISMA的系统综述,检索PubMed和Turning Research into Practice数据库,纳入2012至2023年以英文编写或更新的国家及国际指南。
  • 使用AGREE II工具评价单部指南质量。

主要发现

  • 共纳入41部已发表指南,识别出48条不同推荐:前列腺癌15条(31%),肾癌11条(23%),甲状腺癌6条(12.5%),血液肿瘤10条(21%),其余6条(12.5%)涉及脑、胃肠道、口腔、骨及嗜铬细胞瘤和副神经节瘤癌症。
  • 合并所有指南,48条(100%)说明哪些患者符合监测条件,31条(65%)明确检测项目,25条(52%)提供监测间隔推荐,23条(48%)列出启动干预的触发条件。
  • 在所有癌症部位中,证据级别越高,推荐越具体,呈强阳性趋势(P=0.001);监测间隔的证据基于专家意见或其他指南。

关键数值与推荐

  • 48条推荐:前列腺癌15条(31%)、肾癌11条(23%)、甲状腺癌6条(12.5%)、血液肿瘤10条(21%)、其他6条(12.5%)。
  • 48条(100%)说明监测适用人群,31条(65%)明确检测项目,25条(52%)提供监测间隔,23条(48%)列出干预触发条件。
  • 证据级别与推荐具体性关联的P=0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 除前列腺癌外,低风险癌症监测的证据基础薄弱。
  • 临床指南推荐不一致。
  • 文献缺乏直接证据支持监测推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this systematic review was to summarize national and international guidelines that made recommendations for monitoring patients diagnosed with low-risk cancer. It appraised the quality of guidelines and determined whether the guidelines adequately identified patients for monitoring, specified which tests to use, defined monitoring intervals, and stated triggers for further intervention. It then assessed the evidence to support each recommendation. STUDY DESIGN AND SETTING: Following the Preferred Reporting Items for Systematic Reviews and Meta-analyses, we searched PubMed and Turning Research into Practice databases for national and international guidelines' that were written in English and developed or updated between 2012 and 2023. Quality of individual guidelines was assessed using the AGREE II tool. RESULTS: Across the 41 published guidelines, 48 different recommendations were identified: 15 (31%) for prostate cancer, 11 (23%) for renal cancer, 6 (12.5%) for thyroid cancer, and 10 (21%) for blood cancer. The remaining 6 (12.5%) were for brain, gastrointestinal, oral cavity, bone and pheochromocytoma and paraganglioma cancer. When combining all guidelines, 48 (100%) stated which patients qualify for monitoring, 31 (65%) specified which tests to use, 25 (52%) provided recommendations for surveillance intervals, and 23 (48%) outlined triggers to initiate intervention. Across all cancer sites, there was a strong positive trend with higher levels of evidence being associated with an increased likelihood of a recommendation being specific (P = 0.001) and the evidence for intervals was based on expert opinion or other guidance. CONCLUSION: With the exception of prostate cancer, the evidence base for monitoring low-risk cancer is weak and consequently recommendations in clinical guidelines are inconsistent. There is a lack of direct evidence to support monitoring recommendations in the literature making guideline developers reliant on expert opinion, alternative guidelines, or indirect or nonspecific evidence.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Collins KK, Smith CF, Ford T, et al. Adequacy of clinical guideline recommendations for patients with low-risk cancer managed with monitoring: systematic review. J Clin Epidemiol. 2024. PMID: 38360377. doi:10.1016/j.jclinepi.2024.111280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。